About IDEXX Laboratories (NASDAQ:IDXX)
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Debt
Debt-to-Equity Ratio-11.26%
Current Ratio0.97%
Quick Ratio0.80%
Price-To-Earnings
Trailing P/E Ratio59.89
Forward P/E Ratio47.74
P/E Growth2.46
Sales & Book Value
Annual Sales$1.97 billion
Price / Sales8.68
Cash Flow$4.2259 per share
Price / Cash46.43
Book Value($0.62) per share
Price / Book-316.47
Profitability
EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins13.36%
Return on Equity-432.19%
Return on Assets17.19%
Miscellaneous
Employees7,600
Outstanding Shares87,060,000
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories announced that its Board of Directors has initiated a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, February, 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.73 by $0.04. The business had revenue of $506 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The company's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.58 earnings per share. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided EPS guidance of $4.04-4.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.72. The company issued revenue guidance of $2.205-2.245 billion, compared to the consensus revenue estimate of $2.16 billion.
What price target have analysts set for IDXX?
6 analysts have issued 12 month target prices for IDEXX Laboratories' stock. Their predictions range from $118.00 to $220.00. On average, they anticipate IDEXX Laboratories' stock price to reach $190.6667 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.
What are Wall Street analysts saying about IDEXX Laboratories stock?
Here are some recent quotes from research analysts about IDEXX Laboratories stock:
- 1. According to Zacks Investment Research, "Over the past year, IDEXX has been outperforming its industry. However, its high dependence on third-party distributors and intense competition continue to pose threats. The stock’s overvaluation is also a concern. On a positive note, the company continues to demonstrate solid growth globally on consistent consumable revenue gains. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently commercially launched Catalyst SDMA Test in North America. Solid organic revenue growth along with a raised guidance for 2018 buoys optimism." (4/9/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include Ipsen (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), New England Nuclear (LNTH), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Achieve Life Sciences (ACHV) and BG Medicine (BGMD).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
- Mr. Brian P. McKeon, CFO, Exec. VP, Treasurer & Principal Accounting Officer (Age 56)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Giovani Twigge, Corp. VP & Chief HR Officer (Age 54)
- Mr. Jay Mazelsky, Exec. VP (Age 57)
Has IDEXX Laboratories been receiving favorable news coverage?
Headlines about IDXX stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.04 on Accern's scale. They also gave press coverage about the company an impact score of 46.33 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $196.32.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $17.49 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
IDEXX Laboratories (NASDAQ:IDXX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for IDEXX Laboratories in the last 12 months. Their average twelve-month price target is $190.6667, suggesting that the stock has a possible downside of 2.83%. The high price target for IDXX is $220.00 and the low price target for IDXX is $118.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.67 | 2.67 | 2.43 | 2.33 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $190.6667 | $190.6667 | $176.3333 | $171.60 |
| Price Target Upside: | 2.83% downside | 0.96% downside | 1.79% upside | 7.94% upside |
IDEXX Laboratories (NASDAQ:IDXX) Consensus Price Target History
IDEXX Laboratories (NASDAQ:IDXX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
IDEXX Laboratories (NASDAQ:IDXX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IDEXX Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.56%
Institutional Ownership Percentage: 87.45%
IDEXX Laboratories (NASDAQ IDXX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/28/2018 | Daniel M Junius | Director | Sell | 2,974 | $190.06 | $565,238.44 | 5,602 |  |
| 2/22/2018 | William T End | Director | Sell | 4,000 | $184.48 | $737,920.00 | 41,256 | |
| 2/14/2018 | Lawrence D Kingsley | Director | Buy | 1,000 | $178.05 | $178,050.00 | 4,558 | |
| 2/8/2018 | Jonathan W Ayers | Chairman | Sell | 22,000 | $177.52 | $3,905,440.00 | 1,077,112 | |
| 2/7/2018 | Bruce L Claflin | Director | Buy | 1,000 | $179.58 | $179,580.00 | 1,000 | |
| 2/6/2018 | Jonathan W Ayers | Chairman | Sell | 36,000 | $179.28 | $6,454,080.00 | 1,077,112 | |
| 2/5/2018 | Brian P Mckeon | VP | Sell | 6,602 | $181.36 | $1,197,338.72 | 47,040 | |
| 1/11/2018 | Jonathan W Ayers | CEO | Sell | 2,160 | $167.03 | $360,784.80 | 1,077,112 | |
| 1/9/2018 | Jonathan W Ayers | CEO | Sell | 18,000 | $165.15 | $2,972,700.00 | 1,077,112 | |
| 11/30/2017 | Giovani Twigge | Insider | Sell | 2,000 | $156.07 | $312,140.00 | | |
| 11/16/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $153.61 | $2,764,980.00 | 1,064,573 | |
| 11/14/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $148.35 | $2,670,300.00 | 1,064,573 | |
| 11/7/2017 | Jonathan W Ayers | Chairman | Sell | 54,000 | $151.32 | $8,171,280.00 | 1,064,573 | |
| 11/3/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $153.75 | $2,767,500.00 | 1,064,573 | |
| 8/28/2017 | Jonathan W Ayers | Chairman | Sell | 13,000 | $150.79 | $1,960,270.00 | 1,044,034 | |
| 8/23/2017 | Rebecca M Henderson | Director | Sell | 5,156 | $153.29 | $790,363.24 | 17,274 | |
| 8/22/2017 | Rebecca M Henderson | Director | Sell | 2,578 | $152.86 | $394,073.08 | 17,274 | |
| 8/16/2017 | Jonathan W Ayers | Chairman | Sell | 58,000 | $155.00 | $8,990,000.00 | 1,043,034 | |
| 8/15/2017 | Jonathan W Ayers | CEO | Sell | 20,000 | $154.62 | $3,092,400.00 | 1,043,034 | |
| 8/14/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $154.91 | $2,788,380.00 | 1,043,034 | |
| 8/9/2017 | Jonathan W Ayers | Chairman | Sell | 17,000 | $154.54 | $2,627,180.00 | 1,039,034 | |
| 8/8/2017 | Jonathan W. Ayers | Chairman | Sell | 18,000 | $155.22 | $2,793,960.00 | | |
| 8/3/2017 | Lawrence D Kingsley | Director | Buy | 2,000 | $151.76 | $303,520.00 | 3,344 | |
| 5/31/2017 | Giovani Twigge | Insider | Sell | 2,572 | $166.90 | $429,266.80 | | |
| 5/30/2017 | Jonathan W Ayers | Chairman | Sell | 13,000 | $167.82 | $2,181,660.00 | 1,032,994 | |
| 5/22/2017 | William T End | Director | Sell | 5,000 | $162.55 | $812,750.00 | 45,256 | |
| 5/10/2017 | Jonathan W Ayers | Chairman | Sell | 27,000 | $162.69 | $4,392,630.00 | 1,024,994 | |
| 5/5/2017 | Jonathan W. Ayers | Chairman | Sell | 26,000 | $160.61 | $4,175,860.00 | | |
| 5/4/2017 | Rebecca M Henderson | Director | Sell | 1,700 | $159.95 | $271,915.00 | 21,552 | |
| 3/1/2017 | Lawrence D Kingsley | Director | Buy | 1,000 | $146.48 | $146,480.00 | 1,135 | |
| 2/22/2017 | Jonathan W Ayers | Chairman | Sell | 35,000 | $142.58 | $4,990,300.00 | 995,947 | |
| 2/8/2017 | Brian P Mckeon | VP | Sell | 9,924 | $141.64 | $1,405,635.36 | 45,235 | |
| 2/8/2017 | Daniel M Junius | Director | Sell | 3,000 | $141.75 | $425,250.00 | 5,495 | |
| 2/8/2017 | Jonathan W. Ayers | Chairman | Sell | 36,250 | $141.63 | $5,134,087.50 | | |
| 11/29/2016 | Jonathan W Ayers | Chairman | Sell | 27,424 | $119.77 | $3,284,572.48 | 1,001,043 | |
| 11/28/2016 | Jonathan W Ayers | CEO | Sell | 13,188 | $119.57 | $1,576,889.16 | 1,001,043 | |
| 11/23/2016 | Thomas Craig | Director | Sell | 8,500 | $120.06 | $1,020,510.00 | 32,783 | |
| 11/9/2016 | Jonathan W. Ayers | Chairman | Sell | 40,000 | $107.85 | $4,314,000.00 | | |
| 11/8/2016 | William T End | Director | Sell | 5,000 | $109.87 | $549,350.00 | 48,654 | |
| 8/25/2016 | Rebecca M Henderson | Director | Sell | 9,924 | $110.43 | $1,095,907.32 | 16,678 | |
| 8/15/2016 | Barry C Johnson | Director | Sell | 9,924 | $111.37 | $1,105,235.88 | 13,484 | |
| 8/8/2016 | Michael J. Phd Williams | Insider | Sell | 49,560 | $108.94 | $5,399,066.40 | | |
| 8/5/2016 | William T End | Director | Sell | 5,000 | $108.50 | $542,500.00 | 53,564 | |
| 8/4/2016 | Jonathan W. Ayers | Chairman | Sell | 60,000 | $107.69 | $6,461,400.00 | | |
| 5/5/2016 | William T End | Director | Sell | 4,924 | $85.87 | $422,823.88 | 63,578 | |
| 2/24/2016 | Michael J Phd Williams | EVP | Sell | 2,000 | $71.93 | $143,860.00 | 40,011 | |
| 2/9/2016 | Thomas Craig | Director | Sell | 2,054 | $69.52 | $142,794.08 | 22,298 | |
| 2/8/2016 | Brian P. Mckeon | CFO | Sell | 9,054 | $69.65 | $630,611.10 | 32,461 | |
| 11/30/2015 | Thomas Craig | Director | Sell | 7,000 | $70.28 | $491,960.00 | 22,048 | |
| 11/12/2015 | Rebecca M. Henderson | Director | Sell | 2,300 | $68.39 | $157,297.00 | 21,450 | |
| 8/31/2015 | Thomas Craig | Director | Sell | 800 | $71.77 | $57,416.00 | 21,793 | |
| 8/18/2015 | Michael J. Phd Williams | EVP | Sell | 6,586 | $78.34 | $515,947.24 | 39,654 | |
| 8/18/2015 | Thomas Craig | Director | Sell | 2,900 | $79.41 | $230,289.00 | 22,593 | |
| 8/17/2015 | Jonathan W Ayers | CEO | Sell | 14,799 | $78.45 | $1,160,981.55 | | |
| 5/18/2015 | William T End | Director | Sell | 3,527 | $134.51 | $474,416.77 | | |
| 3/10/2015 | William T End | Director | Sell | 3,500 | $150.89 | $528,115.00 | | |
| 3/4/2015 | Johnny D Powers | EVP | Sell | 6,168 | $158.49 | $977,566.32 | | |
| 2/17/2015 | Brian P Mckeon | CFO | Sell | 5,000 | $156.99 | $784,950.00 | | |
| 2/12/2015 | Jonathan W Ayers | CEO | Sell | 58,245 | $155.45 | $9,054,185.25 | | |
| 2/5/2015 | Rebecca M Henderson | Director | Sell | 2,934 | $156.27 | $458,496.18 | | |
| 2/4/2015 | Thomas Craig | Director | Sell | 2,200 | $157.02 | $345,444.00 | | |
| 1/14/2015 | Jonathan W Ayers | CEO | Sell | 28,512 | $157.68 | $4,495,772.16 | | |
| 12/3/2014 | Jonathan W Ayers | CEO | Sell | 29,000 | $148.49 | $4,306,210.00 | | |
| 11/13/2014 | Thomas Craig | Director | Sell | 5,000 | $152.45 | $762,250.00 | | |
| 11/5/2014 | Jonathan W Ayers | CEO | Sell | 29,000 | $143.45 | $4,160,050.00 | | |
| 11/4/2014 | Johnny D Powers | EVP | Sell | 1,292 | $142.70 | $184,368.40 | | |
| 8/13/2014 | M Anne Szostak | Director | Buy | 2,000 | $127.03 | $254,060.00 | | |
| 2/20/2014 | M Anne Szostak | Director | Buy | 2,000 | $126.71 | $253,420.00 | 5,000 | |
| 2/19/2014 | Thomas Craig | Director | Sell | 4,800 | $125.42 | $602,016.00 | 11,976 | |
| 2/3/2014 | Jonathan Ayers | CEO | Sell | 81,294 | $112.46 | $9,142,323.24 | 389,665 | |
| 11/26/2013 | Jonathan Ayers | CEO | Sell | 78,178 | $105.29 | $8,231,361.62 | 377,211 | |
| 11/22/2013 | Sophie Vandebroek | Director | Buy | 1,000 | $107.84 | $107,840.00 | 1,000 | |
| 11/13/2013 | Jonathan Ayers | CEO | Sell | 78,178 | $106.36 | $8,315,012.08 | 365,389 | |
| 11/4/2013 | M Anne Szostak | Director | Buy | 1,000 | $108.24 | $108,240.00 | 3,000 | |
| 11/4/2013 | Michael Phd Williams | EVP | Sell | 6,020 | $108.19 | $651,303.80 | 11,566 | |
| 10/31/2013 | William T End | Director | Sell | 2,500 | $108.32 | $270,800.00 | | |
| 10/25/2013 | Jonathan W Ayers | CEO | Sell | 78,178 | $104.36 | $8,158,656.08 | | |
| 9/13/2013 | Johnny Powers | EVP | Sell | 13,128 | $96.59 | $1,268,033.52 | 8,989 | |
| 9/5/2013 | Michael J Phd Williams | EVP | Sell | 5,162 | $95.58 | $493,383.96 | | |
| 5/9/2013 | Ali Naqui | VP | Sell | 12,961 | $87.00 | $1,127,607.00 | | |
| 2/4/2013 | Merilee Raines | CFO | Sell | 175,929 | $94.25 | $16,581,308.25 | | |
| 11/13/2012 | Jonathan W Ayers | CEO | Sell | 15,000 | $89.92 | $1,348,800.00 | | |
| 9/5/2012 | Johnny D Powers | EVP | Sell | 4,000 | $97.12 | $388,480.00 | | |
| 8/8/2012 | Merilee Raines | CFO | Sell | 7,726 | $88.84 | $686,377.84 | | |
(Data available from 1/1/2013 forward)
IDEXX Laboratories (NASDAQ IDXX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $525.03 Million
www.americanbankingnews.com - April 16 at 4:00 AM |
| Reviewing IDEXX Laboratories (IDXX) & The Competition
www.americanbankingnews.com - April 15 at 7:18 PM |
| IDEXX Laboratories (IDXX) versus The Competition Financial Review
www.americanbankingnews.com - April 15 at 5:15 PM |
| IDEXX Laboratories (IDXX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 14 at 10:53 PM |
| $0.93 Earnings Per Share Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - April 14 at 7:41 AM |
 | Global Veterinary Molecular Diagnostics Market to Reach US$ 792.5 Mn by 2025, Says TMR
www.prnewswire.com - April 13 at 5:44 PM |
| IDEXX Laboratories (IDXX) & Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 13 at 8:53 AM |
 | IDEXX Laboratories to Release 2018 First Quarter Financial Results
finance.yahoo.com - April 12 at 5:54 PM |
| Edited Transcript of IDXX presentation 6-Mar-17 3:25pm GMT
finance.yahoo.com - April 12 at 5:54 PM |
| Critical Comparison: IDEXX Laboratories (IDXX) & Its Peers
www.americanbankingnews.com - April 12 at 5:27 PM |
| Analyzing IDEXX Laboratories (IDXX) and BG Medicine (BGMD)
www.americanbankingnews.com - April 12 at 3:35 AM |
| IDEXX Laboratories (IDXX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM |
| IDEXX Laboratories (IDXX) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 5 at 9:36 PM |
 | Top Reasons Why I Like Abaxis In 2018
seekingalpha.com - April 4 at 4:25 PM |
| Zacks Investment Research Lowers IDEXX Laboratories (IDXX) to Hold
www.americanbankingnews.com - April 3 at 2:26 PM |
| Head to Head Analysis: IDEXX Laboratories (IDXX) vs. Its Peers
www.americanbankingnews.com - April 2 at 11:21 PM |
| Financial Review: IDEXX Laboratories (IDXX) and The Competition
www.americanbankingnews.com - April 1 at 3:20 PM |
| IDEXX Laboratories, Inc. (IDXX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:30 PM |
| $525.03 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - March 30 at 3:38 AM |
| IDEXX Laboratories (IDXX) Receives New Coverage from Analysts at Piper Jaffray
www.americanbankingnews.com - March 28 at 3:14 PM |
 | IDEXX Launches SDMA in the Point of Care in the United Kingdom and Ireland with IDEXX CatalystSDMA Test
www.finanznachrichten.de - March 26 at 5:31 PM |
| IDEXX Laboratories (IDXX) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 10:03 AM |
 | First Week of May 18th Options Trading For Idexx Laboratories (IDXX) - Nasdaq
www.nasdaq.com - March 23 at 5:56 PM |
| Northcoast Research Equities Analysts Cut Earnings Estimates for IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 23 at 8:28 AM |
| Why Should You Add IDEXX (IDXX) Stock to Your Portfolio? - Nasdaq
www.nasdaq.com - March 22 at 5:48 PM |
| Why Should You Add IDEXX (IDXX) Stock to Your Portfolio?
finance.yahoo.com - March 22 at 5:48 PM |
| IDEXX Laboratories, Inc. Forecasted to Post Q1 2019 Earnings of $1.03 Per Share (IDXX)
www.americanbankingnews.com - March 22 at 1:10 PM |
| Critical Analysis: IDEXX Laboratories (IDXX) vs. Its Competitors
www.americanbankingnews.com - March 19 at 7:43 AM |
| This Morning's Technical Outlook on Healthcare Stocks -- AMAG Pharma, IDEXX Labs, AstraZeneca, and China Pharma - PR Newswire (press release)
www.prnewswire.com - March 14 at 8:12 AM |
| IDEXX Laboratories (IDXX) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - March 11 at 4:45 PM |
| IDEXX Laboratories, Inc. (IDXX) Expected to Announce Earnings of $0.93 Per Share
www.americanbankingnews.com - March 11 at 4:14 AM |
| Idexx Laboratories Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - March 10 at 8:10 AM |
| IDEXX Laboratories, Inc. (IDXX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 7 at 1:51 PM |
| Renaissance Technologies LLC Has $293.96 Million Holdings in IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 6 at 2:52 PM |
| Raymond James Financial Services Advisors Inc. Acquires 3,433 Shares of IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 5 at 10:59 AM |
| IDEXX Laboratories, Inc. (IDXX) Shares Sold by OppenheimerFunds Inc.
www.americanbankingnews.com - March 5 at 10:06 AM |
| IDEXX Laboratories, Inc. (IDXX) Shares Sold by Calamos Advisors LLC
www.americanbankingnews.com - March 5 at 5:35 AM |
| Lombard Odier Asset Management Switzerland SA Boosts Stake in IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 4 at 2:39 PM |
| American International Group Inc. Buys 3,125 Shares of IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 4 at 4:24 AM |
| Assetmark Inc. Sells 10,111 Shares of IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 3 at 4:38 AM |
| Suntrust Banks Inc. Boosts Position in IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - March 2 at 8:24 PM |
| Insider Selling: IDEXX Laboratories, Inc. (IDXX) Director Sells 2,974 Shares of Stock
www.americanbankingnews.com - March 2 at 6:38 PM |
| IDEXX Laboratories, Inc. (IDXX) is Capital Counsel LLC NY's 3rd Largest Position
www.americanbankingnews.com - March 2 at 5:24 AM |
| IDEXX Laboratories, Inc. (IDXX) Stake Decreased by Schroder Investment Management Group
www.americanbankingnews.com - March 1 at 6:32 PM |
| MedTech's Long-Term Prospects Outweigh Near-Term Risks - Nasdaq
www.nasdaq.com - March 1 at 8:04 AM |
| IDEXX Laboratories, Inc. (IDXX) Shares Bought by State of Tennessee Treasury Department
www.americanbankingnews.com - February 28 at 5:47 PM |
| IDEXX Laboratories, Inc. (IDXX) Shares Sold by UBS Asset Management Americas Inc.
www.americanbankingnews.com - February 27 at 4:17 PM |
| IDEXX Laboratories, Inc. (IDXX) Shares Sold by The Manufacturers Life Insurance Company
www.americanbankingnews.com - February 27 at 4:16 PM |
| IDEXX Laboratories, Inc. (IDXX) Position Trimmed by Obermeyer Wood Investment Counsel Lllp
www.americanbankingnews.com - February 27 at 2:04 PM |
| Ontario Teachers Pension Plan Board Acquires 2,564 Shares of IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - February 27 at 12:17 PM |
IDEXX Laboratories (NASDAQ:IDXX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IDEXX Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement
IDEXX Laboratories (NASDAQ IDXX) Stock Chart for Friday, April, 20, 2018
Loading chart…
